Table 1.

Patient Demographics

Variable	No.	%
N	148
Age, y
Median	73
Range	25-86
<65	40	27
65+	108	73
Sex
Male	102	69
Female	46	31
De novo MDS	127	86
Treatment-related MDS	21	14
Median presenting blood counts
Hemoglobin (g/dL)	9.3
Platelet (×103/mm3)	103
Neutrophil (×103/mm3)	1.85
Transfusion dependencea
PRBC	59	40
Platelet	23	16
2008 WHO classification
RCUD	3	2
RARS	24	16
RCMD	38	26
RAEB-1	21	14
RAEB-2	30	20
MDS-U	7	5
MDS with del(5q)	4	3
IPSS
Low	46	31
Int-1	41	28
Int-2	53	36
High	8	5
IPSS-R
Very low	23	16
Low	39	26
Intermediate	25	17
High	27	18
Very high	34	23
Treatmentb
Supportive
Observation	61	41
Growth factor	23	16
Total	84	57
Active
Azacitidine	23	16
Decitabine	9	6
Lenalidomide	10	7
Induction-type chemotherapy	5	3
Total	47	32
Transplant	17	11

^aDefined as having received any PRBC or platelets.

^bPatients placed in only one treatment category based on most aggressive therapy.

Abbreviations: RCUD, refractory cytopenia with unilineage dysplasia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2; MDS-U, myelodysplastic syndrome unclassified.